The Aim of This Study is to Determine if Oocyte Sorting for Group Culture Using an Artificial Intelligence Image Analysis Tool (MagentaTM) Increases the Usable Blastocyst Yield and Subsequent Pregnancy in Patients Undergoing IVF
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Magenta AI image analysis tool.
- Who it may be relevant to
- Registry conditions: Infertility Primary. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
NiOS (Non-Invasive Oocyte Sorting) Study
Overview
The aim of this study is to determine if oocyte sorting for group culture using an artificial intelligence image analysis tool (MagentaTM) increases the usable blastocyst yield and subsequent pregnancy in patients undergoing IVF.
Detailed description
Introduction Magenta™ is a software image analysis tool developed by Future Fertility that allows personalized reproductive prediction for each oocyte (egg cell) analyzed. It is a cloud-based software that was developed to assess the probability of an oocyte to fertilize and develop into a blastocyst (ball of rapidly dividing cells that will become an embryo). It is a non-invasive image analysis tool that uses artificial intelligence (AI) to predict outcomes based on a single 2-D image of a mature oocyte (denuded oocyte) prior to freezing or sperm injection (ICSI). Magenta™ was designed and built specifically to analyze oocytes in the IVF lab. It was created based on more than 20,000 images of oocytes and their known reproductive outcomes. It is an image analysis neural network that can identify important signals beyond the limited morphological features detected by embryologists, like facial recognition systems in use today. Without the development of this AI tool, there are no standard assessments for oocyte quality within the IVF process. The use of Magenta™ in this study is investigational.
In standard IVF laboratories, oocytes can undergo their developmental period alone (single culture) or be grouped with other oocytes during this time (group culture). Research has shown that group culture has some developmental advantages over single culture.
What is this study for? At the moment, there is no standard method to sort oocytes into groups for their developmental period. Currently, oocytes are sorted in a random manner. We hope that Magenta™ analysis will provide information at this early stage of development and inform a better way to sort oocytes into groups (from lowest to highest quality). The objective of this research study is to compare sorting the oocytes randomly to utilizing the MagentaTM tool for oocyte assessment to determine which oocytes should be grouped together. Study participants will be randomly assigned to the control (random sorting) or the study (Magenta™ analysis) groups at the time of oocyte retrieval. You have an equal chance of being assigned to either group. We intend to enroll 450 subjects.
Interventions
- Other Magenta AI image analysis tool
MagentaTM is a non-invasive image analysis tool that utilizes artificial intelligence to evaluate 2-dimensional images of denuded mature MII oocytes. The MagentaTM software has been analyzed retrospectively, by Future Fertility. This data displays that a higher MagentaTM score is associated with a higher chance of blastocyst development. Additionally, the MagentaTM software has been validated in a prospective multi-center study, displaying that a higher MagentaTM score correlates to a higher cha
Primary outcome measures
- Compare blastocyst development rate [Time frame: 5 to 7 days]
Secondary outcome measures (4)
- Fertilization Rate [Time frame: 1Day]
- Morphological Blastocyst Quality [Time frame: 7 days]
- Euploidy Rate [Time frame: 14 days]
- Pregnancy Rate [Time frame: 6 weeks]
Eligibility criteria
Inclusion criteria
- Fresh MII oocytes
- ICSI cycles with patient's or donor's sperm
- Patient's or donor's oocytes
- Full IVF cycle information available (including total number of oocytes retrieved, total MII oocytes, fertilization, embryo and blastocyst development, as well as ploidy status or implantation results, and 6-7 week ultrasound, if applicable)
- Good quality images of MII oocytes taken with a specified camera (Basler) and Future Fertility Software
- Single embryo transfers (SETs) at blastocyst stage.
- Blastocyst freeze-all cycles
Exclusion criteria
- Severe male factor infertility (<1 million motile), including surgically retrieved sperm.
- ICSI cycles inseminating in vitro matured (IVM) oocytes
- Rescue ICSI oocytes (oocytes failed standard IVF and are re-inseminated by ICSI)
- Low quality images - Poor quality images on day of upload or before unblinding
- Lack of correlating reproductive outcomes (full IVF lab results not available).
- Autologous or donor frozen/warmed oocytes
- Day 3 embryo transfers or cleavage stage embryo freezing
- Patients with less than 6 mature oocytes
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
United States · 3 centers
- Ovation Fertility Las Vegas — Las Vegas
- Ovation Fertility Cincinnati — Cincinnati
- Ovation Fertility - Nashville — Nashville
Identifiers
NCT: NCT06521372 · OVA-11-2023-TX